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in 1.2% of patients in the pre-mask period and 0.2% in the
mask period (P ¼ .12). Patients with RVI required more peri-
transplant care (median 76 days vs. 21 days, P< .0001). These
data suggest that requiring all individuals with direct patient
contact to wear a surgical mask can reduce the incidence of
RVI, particularly PIV3, during the vulnerable period following
HSCT.322
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Transplant-Associated Toxicities in Patients with Multiple
Myeloma?
Juan J. Toro, Deanna Schneider, Shuko Lee, Gregory M. Smith,
Francisca Gushiken, David J. Haile, Cesar O. Freytes. South
Texas Veterans Health Care System, San Antonio, TX
Objective: Previous studies suggest that edentulous
(subjects without teeth) have a lower inﬂammatory state
than non-edentulous individuals probably due to peri-
odontal infection in non-edetulous subjects. We hypothe-
sized that edentulous patients would have a lower incidence
of bacteremia and other complications associated with
autotransplantation for multiple myeloma (MM).
Methods: We conducted a retrospective case-control study
of patients who received autologous hematopoietic stem cell
transplantation (AHSCT) for multiple MM at the Audie L.
Murphy Memorial Veterans Hospital Bone Marrow Trans-
plant Unit, in San Antonio, Texas from January 2003 through
September 2012. Case subjects were deﬁned as edentulous
and controls were deﬁned as non-edentulous. The 2 groups
were matched for age, gender, ethnicity, MM stage, time
from diagnosis to transplant, performance status, and
conditioning regimen. The following posttransplant toxic-
ities were analyzed: bacteremia, oral mucositis, nausea/
vomiting, diarrhea, neutrophil engraftment and length of
hospital stay.Table 1
Post-AHSCT patient toxicities
Edentulous
N¼45
Control Group
N¼90
P-value
Bacteremia, n (%) 0.553
Yes 11 (24) 18 (20)
No 34 (76) 72 (80)
Oral mucositis, n (%) 0.465
Grade 0 13 (29) 33 (37)
Grade 1 16 (36) 21 (23)
Grade 2 13 (29) 27 (30)
Grade 3 3 (7) 9 (10)
Nausea/Vomiting, n (%) 0.744
Grade 0 4 (9) 7 (8)
Grade 1 24 (53) 40 (44)
Grade 2 14 (31) 36 (40)
Grade 3 3 (7) 7 (8)
Diarrhea, n (%) 0.095
Grade 0 6 (13) 10 (11)
Grade 1 7 (16) 17 (19)
Grade 2 15 (33) 24 (27)
Grade 3 14 (31) 39 (43)
Grade 4 3 (7) 0 (0)
Days to ANC engraftment 0.966
Mean (SD) 10.84 (1.80) 10.83 (1.16)
Range 8-31 9-17
Length of hospital stay
(days)
0.098
Mean (SD) 15.76 (4.94) 17.47 (5.99)
Range 3-30 3-52Results: During the study period, 297 AHSCT were per-
formed at our institution. Of these, 45 (15%) patients were
found to be edentulous at the time of ﬁrst AHSCT. Forty-
ﬁve case subjects were matched to 90 controls. All
patients were males, their median age was 60 years
(range, 42-75), their Karnofsky performance status score
mean was 90 (range, 70-90), and all received melphalan as
part of the conditioning regimen. The majority of patients,
90 (67%) had stage III MM at transplantation and the
median time from diagnosis to transplantation was 12
months (range, 4-103).
The incidence and severity of all posttransplant toxicities
analyzed were similar in both groups (see Table 1). Thirty-
eight (84%) of edentulous patients were smokers or had
a history of smoking at the time of AHSCT compared to 58
(64%) of the control group (P ¼ .016). Overall survival after
transplant was similar in both groups.
Conclusions: The incidence of toxicities after AHSCT
experienced by edentulous MM patients was similar to
controls including bacteremia and oral mucositis. There
was a strong association between edentulism and
smoking.323
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Microbiologically conﬁrmed infections (MCI) which occur
during stem cell transplantation (HSCT) increase morbidity
andmortality. HSCT recipients who develop polymicrobial or
multiple microbiologically conﬁrmed infections (MMCI) may
be at increased risk for unfavorable outcomes, yet data is
limited. Herein we report the incidence, risk factors and
survival associated for polymicrobial and multiple microbi-
ologically conﬁrmed infections (MMCI) in 901 HSCT
recipients.
Electronic databases were used for HSCT recipients treated at
Northwestern Memorial Hospital between 2004-09. Infec-
tion data was recorded from the time of admission through
discharge. Any single CONS or VRE BAL culture was excluded
from analysis. Patients received acyclovir, azole antifungal,
and ﬂouroquinolone for prophylaxis. Polymicrobial infection
was deﬁned as the occurrence of 2 MCI's from different
organisms within 72 hours of the 1st positive culture.
Fischers Exact test and Chi-Square was used for analysis of
continuous and discreet variables. This study is IRB
approved.
Amongst 905 HSCT recipients, 59 patients (6.8%) developed
MMCI's. Polymicrobial infection was identiﬁed in 30 (3.4%)
patients. 17 patients had > 2MCI's. Most MCI's (55%) were
blood stream infections. The duration of time which tran-
spired between positive cultures was as follows: Con-
commitant cultures (n¼13), <24 hr (n¼9), 48 hr (n¼8), <72
hr (n¼5), <96 hr (n¼4), <120 hr (n¼3), <144hr (n¼5), >7
days(n¼12). When MMCI'S cases were compared to patients
without any positive cultures using bivariate analysis,
statistically signiﬁcant differences included : female gender
(0.0377), diagnosis of myeloma (P < .0133) or AML (P <
.0497), receipt of allo-HSCT (P < .0001), vancomycin (P <
.0004)or cefepime(P < .0005) use, and positive VRE
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compared to single MCI cases, signiﬁcant differences
included: female gender (P< .0349), receipt of allo-HSCT (P<
.0373), vancomycin (P< .0012) and cefepime (P < .0009) use.
There was no difference in the number of patients who
experienced neutropenic fever between MMCI, MCI (P <
.275) or culture negative cases (P < .1247). Strept mitis or
C.difﬁcileinfection occurred concommitantly or preceded the
second MCI in 29(47%) cases. Overall mortality was signiﬁ-
cantly higher in MMCI cases when compared to cases
without any positive cultures (P < .001) or patients with
a single MCI (P < .0197). There was no difference in overall
mortality for patients who developed MMCI <72hours
(polymicrobial) versus MMCI>72 (non-polymicrobial; P <
.2990).
MMCI are an infrequent but serious cause of adverse events
which occur during HSCT. Patients who are at high risk for
developing MMCI require increased vigilance and early
aggressive antibiotic therapy.POSTER SESSION 1: TRANSPLANT DATA MANAGEMENT324
Reduce Errors and Past Due Reports Via Monthly Audits
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Background: In 2004, the National Marrow Donor Pro-
gram's database merged with the International Bone
Marrow Transplant Registry to streamline transplant
research. To manage the fusion of forms generated in two
separate databases, the Center for International Blood and
Marrow Transplant Research (CIBMTR) began assigning
each patient a unique Recipient Identiﬁcation Number
(CRID) in 2007. This has allowed transplant outcomes to be
reported annually, because forms are now automatically
generated for each CRID. Our center created a secure CRID
spreadsheet to manage the merge and track form due dates
(Figure 1). The spreadsheet has evolved into an auditing
tool, serving to simplify our form assignment process and
improve quality.
Best Practices: Using Forms Net, a designated Protocol
Coordinator (PC) generates a monthly list of forms due for
the next ﬁve week reporting period. Next, the list is exported
to an excel spreadsheet allowing the PC to assign forms to
Data Coordinators (DC's) with a DC due date set two weeks
prior to the ﬁnal due date in FormsNet. After the forms are
assigned, DC's use the CRID spreadsheet to cross reference
CRID numbers with Medical Record Numbers (MRN) to
identify the corresponding patient to complete forms. The PC
reviews each form using the CRID spreadsheet to track any
errors made by the DC completing the form. Next, the
audited forms are returned to the DC who corrects and
reprocess the form in FormsNet. Each quarter, a designated
DC cross references the CRID spreadsheet with Forms Net to
ensure error correction and data quality. The spreadsheet can
also be used as an opportunity to re-educate DC's on
frequently missed ﬁelds and reduce errors on the following
month's forms.Outcomes: In the 2008 CIBMTR audit, our center's critical
ﬁeld error rate was 4.2%. Subsequently, implementation of
the secure CRID spreadsheet helped reduce our 2012 critical
ﬁeld error rate to 1.7%. This tool will continue increasing
data quality and reporting outcomes while concomitantly
helping us reach our department goal of <1% error rate in
2016.
Figure 1.325
Timely Capture of Relevant Data for CIBMTR
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Introduction: Each hematopoietic stem cell transplant
(HSCT) performed and fully reported to CIBMTR generates
key information to support research that has cumulatively
led to increased survival and enriched quality of life of
thousands of patients. Between 50 and 60 HSCT (autolo-
gous, related and unrelated) are now annually performed
at the Pediatric Oncology Institute, São Paulo, Brazil. The
program started in 1999 and the ﬁrst 167 transplants
were reported by physicians and by the Cell Processing
Laboratory staff. However, over the past 4 years, the
institution was unable to keep up with the reporting
schedule due to increasing working load. In February
2012, the effort to report all new and old patients to
CIBMTR was resumed.
Objective: To report and share the strategy used to have all
629 forms efﬁciently updated and reported within 8
months.
Methods: The institutional efforts started by hiring
a trained CRA part time devoted to CIBMTR data manage-
ment. A very useful and comprehensive Excel-based
spreadsheet was developed to have visual display of all due
dates with colorful ﬂags and automatic updates to the
current date. Work ﬂows were developed to capture data
during weekly medical rounds. All sources of medical
information e charts, laboratory and radiological reports,
medical round reports - were accessed whenever necessary
and included in the patient charts as documented source of
information. All forms were weekly reviewed with a senior
physician to ensure appropriate training and education of
the new CRA.
Results: A total of 360 patients underwent HSCT between
1999 and September 2012. The CIBMTR forms had been
last updated in 2008 and no new patients were registered
since then. All information that posed the greatest
